Pharvaris N.V.

Pharvaris N.V.

29.85
EUR
0.00
(0.00%)
-2.69EPS
1.98BMarket Cap
Apr 08Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.14
-0.25
-0.85
-1.41
-2.27
-2.63
-2.48
-2.97
-2.69
Free Cash Flow per Basic Share
- -
-0.12
-0.21
-0.71
-1.47
-2
-2.43
-2.23
-2.32
-2.48
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.15
0.16
0.61
3.14
6.18
4.41
7.34
4.92
4.16
3.74
Tangible Book Value per Share
0.15
0.16
0.61
3.14
6.18
4.41
7.34
4.92
4.16
3.74
Basic Weighted Avg Shares
31
32
32
31
30
34
38
54
59
67
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-4
-8
-26
-43
-76
-101
-134
-176
-181
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
5
5
19
96
205
149
383
266
270
264
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
1
- -
Total Equity
5
5
19
96
205
149
384
268
271
265
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-89.78
-67.95
-45.41
-28.42
-43.1
-37.83
-41.18
-65.19
-62.78

Capital Structure

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
65
70
71
Market Capitalization
1,596
2,131
1,982

Working Capital

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
258
327
293
Cash, Cash Equivalents & STI
247
318
283
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
23
27
30
Payables & Accruals
16
19
19
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
43.03%
1.31%
Free Cash Flow
- -
47.95%
13.73%
Net Income, GAAP
- -
47.84%
30.9%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.52
-0.55
-0.77
-0.64
-2.48
2025
-0.85
-0.83
-0.6
-0.72
-2.97
2026
-0.6
-0.7
-0.67
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Berndt A. E. Modig
Full Time Employees
129
Sector
Health technology
Industry
Biotechnology
Address
Grafenauweg 8 Leiden ZH Netherlands 6300
IPO Date
Feb 5, 2021
Business
Pharvaris N.V. (Nasdaq: PHVS) is a late-stage biopharmaceutical company focused on developing novel oral bradykinin B2 receptor antagonists for the treatment and prevention of bradykinin-mediated diseases, including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Founded in 2015 and headquartered in Zug, Switzerland, with operations in the Netherlands and the United States, the company advances deucrictibant as its lead candidate: PHVS416, an immediate-release softgel capsule for on-demand HAE attack treatment; and PHVS719, an extended-release tablet for prophylactic use. Its pipeline targets patients aged 12 and older across global markets, with pivotal Phase 3 trials conducted in 24 countries. In December 2025, Pharvaris announced positive topline results from the RAPIDe-3 Phase 3 trial of deucrictibant immediate-release capsules, meeting the primary endpoint of median time to onset of symptom relief at 1.28 hours versus over 12 hours for placebo, and achieving all 11 secondary endpoints including rapid symptom resolution; topline data from the ongoing CHAPTER-3 prophylactic trial is expected in the second half of 2026, with a U.S. New Drug Application submission planned for the first half of 2026. Earlier in July 2025, the company completed an upsized $175 million underwritten public offering of ordinary shares to fund late-stage clinical programs, U.S. commercialization efforts including sales and marketing team hiring, and general corporate purposes.

Company News

  • Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?

  • Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

  • Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update

  • Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

  • Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade

  • Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

  • Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

  • Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stock

  • Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 Shares

  • Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

  • Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC

  • Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • PHVS Stock Rises 10% in a Month: What Is Driving the Rally?

  • Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win

  • Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript

  • Pharvaris' genetic disorder drug meets main goal in late-stage trial

  • Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

  • Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

  • Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

  • BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS